

Press Release	Contact:
<b>INVESTOR RELATIONS</b> Ashish Girotra <a href="mailto:ashishg@drreddys.com">ashishg@drreddys.com</a> (Ph: +1 6093756145)	<b>MEDIA RELATIONS</b> Lori McCreary <a href="mailto:lmccreary@drreddys.com">lmccreary@drreddys.com</a> (Ph: +1 6093752995)

107 College Road East  
Princeton, NJ 08540  
[www.promiuspharma.com](http://www.promiuspharma.com)

## **Promius Pharma to Present 3 Posters, Including a Podium Presentation, from MAST Study—the Largest Online Longitudinal Epidemiological Survey of Episodic/Chronic Migraine in the United States**

Princeton, NJ, USA. September 7, 2017 – Promius Pharma LLC announced today that it is presenting 3 posters, including a podium presentation, from the 2017 Migraine in America Symptoms and Treatment (MAST) Study at the 18th Congress of the International Headache Society (IHC) in Vancouver, BC, Canada, September 7-10, 2017:

- Predictors of Allodynia in Persons with Migraine: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study
- Untangling the Burden of Menstrual Migraine from Headache Day Frequency: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study
- Factors Associated with Acute Medication Overuse in Persons with Migraine: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study

With data collected from more than 15,000 migraine sufferers, the presentations represent results from the first study in a series of 3 studies that will enhance current knowledge of symptoms and treatment patterns in patients. The second and third studies will provide follow-up at 6 and 12 months, respectively.

Promius Pharma initiated MAST to address gaps in knowledge due to changing demographics and treatment options in the US migraine community. MAST seeks to shed light on the current state of migraine symptom characteristics, including the most bothersome migraine symptoms and how pain interferes with daily functioning. MAST will also illustrate the state of migraine treatment, including medication use and overuse, patterns of treatment delays, and barriers to access.

“The MAST study continues to provide critical insight into the journey of patients suffering from migraine,” said Richard B. Lipton, MD, Director of Montefiore Headache Center. “Our findings enable us to better understand migraine, and devise new strategies to provide relief.”

### **About Promius Pharma LLC**

Promius Pharma is a wholly owned subsidiary of Dr. Reddy’s Laboratories, one of the largest and most respected pharmaceutical companies in the world. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patients’ needs in dermatology and neurology. For more information, visit [www.promiuspharma.com](http://www.promiuspharma.com).

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.

**Press Release**

**Contact:**

**INVESTOR RELATIONS**

Ashish Girotra  
[ashishg@drreddys.com](mailto:ashishg@drreddys.com)  
(Ph: +1 6093756145)

**MEDIA RELATIONS**

Lori McCreary  
[lmccreary@drreddys.com](mailto:lmccreary@drreddys.com)  
(Ph: +1 6093752995)

107 College Road East  
Princeton, NJ 08540  
[www.promiuspharma.com](http://www.promiuspharma.com)

**Contact information:**

Promius Pharma, LLC  
107 College Rd E  
Princeton, NJ 08540  
[www.promiuspharma.com](http://www.promiuspharma.com)

**Investor Relations:**

Ashish Girotra (USA)  
[ashishg@drreddys.com](mailto:ashishg@drreddys.com)  
+1 (609) 375-6145

**Media Relations:**

Lori McCreary (USA)  
[lmccreary@drreddys.com](mailto:lmccreary@drreddys.com)  
+1 (609) 375-2995

Copyright 2017 Promius Pharma, LLC

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.